Trial Profile
Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2022
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary) ; Gallium (68Ga) gozetotide (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms PSMA vs AXUMIN
- 19 Oct 2022 According to Blue Earth Diagnostics media release, data from this study will be presented at the upcoming American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, from October 23 to 26, 2022.
- 31 May 2020 Results (n=787) of post hoc retrospective analysis from four studies (NCT02940262, NCT03515577, NCT04050215, NCT03582774) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.